{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:03:10Z","timestamp":1793138590991,"version":"4.5.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biomarin","id":[{"id":"https:\/\/ror.org\/03fmvqd28","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PTC Therapeutics","id":[{"id":"https:\/\/ror.org\/03jz67a83","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sarepta"},{"name":"Shire (now Takeda)"},{"name":"Collaborative Trajectory Analysis Project"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221097","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T15:01:07Z","timestamp":1567522867000},"page":"e0221097","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":96,"title":["Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":true,"given":"Francesco","family":"Muntoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Domingos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y.","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mayhew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The UK NorthStar Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"pone.0221097.ref001","author":"AEH Emery","year":"2015","edition":"4th ed"},{"issue":"6","key":"pone.0221097.ref002","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"EP Hoffman","year":"1987","journal-title":"Cell"},{"issue":"1","key":"pone.0221097.ref003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/cjn.2015.311","article-title":"A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies","volume":"43","author":"JK Mah","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"pone.0221097.ref004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/oxfordjournals.bmb.a071623","article-title":"Clinical features and classification of the muscular dystrophies","volume":"36","author":"D. Gardner-Medwin","year":"1980","journal-title":"Br Med Bull"},{"key":"pone.0221097.ref005","unstructured":"National Institute of Neurological Disorders and Stroke (NINDS). Muscular Dystrophy Information 2017 [February 8, 2017]. Available from: https:\/\/www.ninds.nih.gov\/Disorders\/All-Disorders\/Muscular-Dystrophy-Information-Page."},{"issue":"3","key":"pone.0221097.ref006","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","article-title":"Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study","volume":"77","author":"E Mazzone","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"pone.0221097.ref007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study\u2014a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"1","key":"pone.0221097.ref008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"K Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"pone.0221097.ref009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"D Gloss","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"pone.0221097.ref010","first-page":"Cd003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"E Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0221097.ref011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"DJ Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0221097.ref012","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"V Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10119","key":"pone.0221097.ref013","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"CM McDonald","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"pone.0221097.ref014","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"L Bello","year":"2015","journal-title":"Neurology"},{"issue":"9791","key":"pone.0221097.ref015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"S Cirak","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"pone.0221097.ref016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"JR Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"10101","key":"pone.0221097.ref017","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"CM McDonald","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"pone.0221097.ref018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"E Scott","year":"2012","journal-title":"Physiother Res Int"},{"issue":"7","key":"pone.0221097.ref019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a multicentric setting","volume":"19","author":"ES Mazzone","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"pone.0221097.ref020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1017\/S0012162206001137","article-title":"Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool","volume":"48","author":"E Scott","year":"2006","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"pone.0221097.ref021","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","article-title":"North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy","volume":"20","author":"E Mazzone","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"pone.0221097.ref022","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/dmcn.12220","article-title":"Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"55","author":"AG Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"pone.0221097.ref023","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.nmd.2016.01.003","article-title":"Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study","volume":"26","author":"S Messina","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"pone.0221097.ref024","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"V Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"pone.0221097.ref025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","article-title":"DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study","volume":"87","author":"L Bello","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"pone.0221097.ref026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JND-140002","article-title":"Prolonged Ambulation in Duchenne Patients with a Mutation Amenable to Exon 44 Skipping","volume":"1","author":"JC van den Bergen","year":"2014","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"pone.0221097.ref027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-150100","article-title":"Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype","volume":"2","author":"L Servais","year":"2015","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"pone.0221097.ref028","doi-asserted-by":"crossref","first-page":"e52512","DOI":"10.1371\/journal.pone.0052512","article-title":"24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy","volume":"8","author":"ES Mazzone","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"pone.0221097.ref029","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"M Pane","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"pone.0221097.ref030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"E Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"16","key":"pone.0221097.ref031","first-page":"P3","article-title":"ACT DMD: Effect of Ataluren on Timed Function Tests (TFTs) in Nonsense Mutation Duchenne Muscular Dystrophy","volume":"86","author":"N Goemans","year":"2016","journal-title":"Neurology"},{"key":"pone.0221097.ref032","unstructured":"Clinical Trials.gov. Study of SRP-4045 and SRP-4053 in DMD Patients (ESSENCE) (Identifer: NCT02500381) 2017 [February 8, 2017]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02500381."},{"key":"pone.0221097.ref033","unstructured":"Clinical Trials.gov. Phase I\/II Study of SRP-4053 in DMD Patients (Identifier: NCT02310906) Bethesda (MD): National Library of Medicine (US); 2014 [January 23, 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02310906?term=NCT02310906&rank=1."},{"key":"pone.0221097.ref034","unstructured":"Clinical Trials.gov. An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy (Identifier: NCT02907619) Bethesda (MD): National Library of Medicine (US); 2016 [January 23, 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02907619?term=NCT02907619&rank=1."},{"key":"pone.0221097.ref035","unstructured":"Clinical Trials.gov. Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy (Identifier: NCT03039686) Bethesda (MD): National Library of Medicine (US); 2017 [January 23, 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03039686?term=NCT03039686&rank=1."},{"issue":"16","key":"pone.0221097.ref036","volume":"86","author":"K Bushby","year":"2016","journal-title":"Results of North Star Ambulatory Assessments (NSAA) in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD) Neurology"},{"issue":"2","key":"pone.0221097.ref037","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10802-014-9898-1","article-title":"Developmental trajectories of anxiety and depression in early adolescence","volume":"43","author":"KA McLaughlin","year":"2015","journal-title":"J Abnorm Child Psychol"},{"issue":"3","key":"pone.0221097.ref038","doi-asserted-by":"crossref","first-page":"e001378","DOI":"10.1161\/JAHA.114.001378","article-title":"Ten-year blood pressure trajectories, cardiovascular mortality, and life years lost in 2 extinction cohorts: the Minnesota Business and Professional Men Study and the Zutphen Study","volume":"4","author":"SM Tielemans","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"pone.0221097.ref039","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.neurobiolaging.2014.12.015","article-title":"Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing","volume":"36","author":"RH Pietrzak","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"7","key":"pone.0221097.ref040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/sim.4137","article-title":"Incorporating scientific knowledge into phenotype development: penalized latent class regression","volume":"30","author":"JM Leoutsakos","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"pone.0221097.ref041","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10705511.2012.634722","article-title":"Poisson Growth Mixture Modeling of Intensive Longitudinal Data: An Application to Smoking Cessation Behavior","volume":"19","author":"MP Shiyko","year":"2012","journal-title":"Struct Equ Modeling"},{"issue":"27","key":"pone.0221097.ref042","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/sim.3721","article-title":"Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling","volume":"28","author":"B Muthen","year":"2009","journal-title":"Stat Med"},{"issue":"2","key":"pone.0221097.ref043","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpsychires.2009.06.006","article-title":"Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder","volume":"44","author":"AM Hunter","year":"2010","journal-title":"J Psychiatr Res"},{"issue":"2","key":"pone.0221097.ref044","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.0006-341X.1999.00463.x","article-title":"Finite mixture modeling with mixture outcomes using the EM algorithm","volume":"55","author":"B Muthen","year":"1999","journal-title":"Biometrics"},{"issue":"6","key":"pone.0221097.ref045","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1530-0277.2000.tb02070.x","article-title":"Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes","volume":"24","author":"B Muthen","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"pone.0221097.ref046","article-title":"Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach","author":"C Proust-Lima","year":"2015","journal-title":"Stat Med"},{"issue":"1","key":"pone.0221097.ref047","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"K Liang","year":"1986","journal-title":"Biometrika"},{"issue":"6","key":"pone.0221097.ref048","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","article-title":"The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations","volume":"42","author":"CM McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"4","key":"pone.0221097.ref049","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.880050405","article-title":"Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy","volume":"5","author":"OM Scott","year":"1982","journal-title":"Muscle Nerve"},{"issue":"10","key":"pone.0221097.ref050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"T Voit","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10","key":"pone.0221097.ref051","doi-asserted-by":"crossref","first-page":"e0164684","DOI":"10.1371\/journal.pone.0164684","article-title":"Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy","volume":"11","author":"N Goemans","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"pone.0221097.ref052","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"A Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"issue":"10","key":"pone.0221097.ref053","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp-2014-308409","article-title":"Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants","volume":"86","author":"JC van den Bergen","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"pone.0221097.ref054","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ana.24370","article-title":"Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study","volume":"77","author":"L Bello","year":"2015","journal-title":"Ann Neurol"},{"issue":"3","key":"pone.0221097.ref055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.0b013e318207afeb","article-title":"SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy","volume":"76","author":"E Pegoraro","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"pone.0221097.ref056","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ajhg.2016.08.023","article-title":"Association Study of Exon Variants in the NF-kappaB and TGFbeta Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy","volume":"99","author":"L Bello","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"2","key":"pone.0221097.ref057","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.25283","article-title":"Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy","volume":"84","author":"RB Weiss","year":"2018","journal-title":"Ann Neurol"},{"issue":"5","key":"pone.0221097.ref058","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","article-title":"Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression","volume":"24","author":"RJ Willcocks","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"pone.0221097.ref059","doi-asserted-by":"crossref","first-page":"e106435","DOI":"10.1371\/journal.pone.0106435","article-title":"Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study","volume":"9","author":"SC Forbes","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"pone.0221097.ref060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mus.26161","article-title":"Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history","volume":"58","author":"H Arora","year":"2018","journal-title":"Muscle Nerve"},{"key":"pone.0221097.ref061","unstructured":"Clinical Trials.gov. Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 Skipping (Identifier: NCT03218995) Bethesda (MD): National Library of Medicine (US); 2017 [January 23, 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03218995?term=NCT03218995&rank=1."},{"key":"pone.0221097.ref062","unstructured":"Clinical Trials.gov. Systemic Gene Delivery Clinical Trial for Duchenne Muscular Dystrophy (Identifier: NCT03375164) Bethesda (MD): National Library of Medicine (US); 2017 [January 23, 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03375164?term=NCT03375164&rank=1."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T12:45:45Z","timestamp":1589028345000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221097"}},"subtitle":[],"editor":[{"given":"Daniel","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221097","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}